Cargando…
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
BACKGROUND: Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers. However, rare studies have evaluated the potential roles of sPD-L1, and no study has estimated its predictive value for t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837921/ https://www.ncbi.nlm.nih.gov/pubmed/36639643 http://dx.doi.org/10.1186/s12967-023-03879-0 |
_version_ | 1784869174951018496 |
---|---|
author | He, Yinjun Zhang, Xiang Zhu, Ming He, Wenguang Hua, Hanju Ye, Feng Zhou, Xile Chen, Nan Li, Yandong Zhong, Weixiang Wu, Guosheng Cai, Hui Jiang, Weiqin |
author_facet | He, Yinjun Zhang, Xiang Zhu, Ming He, Wenguang Hua, Hanju Ye, Feng Zhou, Xile Chen, Nan Li, Yandong Zhong, Weixiang Wu, Guosheng Cai, Hui Jiang, Weiqin |
author_sort | He, Yinjun |
collection | PubMed |
description | BACKGROUND: Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers. However, rare studies have evaluated the potential roles of sPD-L1, and no study has estimated its predictive value for the efficacy of immune treatment in colorectal cancer (CRC). METHODS: Plasma samples from 192 CRC patients were used to estimate correlations between clinicopathological features and sPD-L1, secreted PD-L1 (secPD-L1) and exosomal PD-L1 (exoPD-L1). Baseline and posttreatment sPD-L1 levels were also investigated in 55 patients with metastatic CRC (mCRC) treated with chemotherapy ± targeted therapy and 40 patients with proficient mismatch repair (pMMR) mCRC treated with combination immunotherapy. Both sPD-L1 and secPD-L1 were quantified by enzyme-linked immunosorbent assay, while exoPD-L1 was analyzed using flow cytometry. RESULTS: secPD-L1 was the major component and positively correlated with sPD-L1 in CRC, while exoPD-L1 was almost undetectable. Higher levels of sPD-L1 were detected in patients with distant metastasis, especially those with distant lymph node metastasis and tissue combined positive score (CPS) instead of tumor proportion score (TPS). Chemotherapy or targeted therapy did not significantly impact sPD-L1 concentration. Progressive disease on combination immunotherapy was associated with an increase in sPD-L1 level, whereas no significant change was observed in patients with durable clinical benefit. CONCLUSION: sPD-L1 mainly consisted of secPD-L1, and its level was higher in patients with distant metastasis, especially distant lymph node metastasis and positive CPS. sPD-L1 is a potential dynamic marker to identify rapid progression on combination immunotherapy and avoid ineffective treatment for pMMR CRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03879-0. |
format | Online Article Text |
id | pubmed-9837921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98379212023-01-14 Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer He, Yinjun Zhang, Xiang Zhu, Ming He, Wenguang Hua, Hanju Ye, Feng Zhou, Xile Chen, Nan Li, Yandong Zhong, Weixiang Wu, Guosheng Cai, Hui Jiang, Weiqin J Transl Med Research BACKGROUND: Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers. However, rare studies have evaluated the potential roles of sPD-L1, and no study has estimated its predictive value for the efficacy of immune treatment in colorectal cancer (CRC). METHODS: Plasma samples from 192 CRC patients were used to estimate correlations between clinicopathological features and sPD-L1, secreted PD-L1 (secPD-L1) and exosomal PD-L1 (exoPD-L1). Baseline and posttreatment sPD-L1 levels were also investigated in 55 patients with metastatic CRC (mCRC) treated with chemotherapy ± targeted therapy and 40 patients with proficient mismatch repair (pMMR) mCRC treated with combination immunotherapy. Both sPD-L1 and secPD-L1 were quantified by enzyme-linked immunosorbent assay, while exoPD-L1 was analyzed using flow cytometry. RESULTS: secPD-L1 was the major component and positively correlated with sPD-L1 in CRC, while exoPD-L1 was almost undetectable. Higher levels of sPD-L1 were detected in patients with distant metastasis, especially those with distant lymph node metastasis and tissue combined positive score (CPS) instead of tumor proportion score (TPS). Chemotherapy or targeted therapy did not significantly impact sPD-L1 concentration. Progressive disease on combination immunotherapy was associated with an increase in sPD-L1 level, whereas no significant change was observed in patients with durable clinical benefit. CONCLUSION: sPD-L1 mainly consisted of secPD-L1, and its level was higher in patients with distant metastasis, especially distant lymph node metastasis and positive CPS. sPD-L1 is a potential dynamic marker to identify rapid progression on combination immunotherapy and avoid ineffective treatment for pMMR CRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03879-0. BioMed Central 2023-01-13 /pmc/articles/PMC9837921/ /pubmed/36639643 http://dx.doi.org/10.1186/s12967-023-03879-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research He, Yinjun Zhang, Xiang Zhu, Ming He, Wenguang Hua, Hanju Ye, Feng Zhou, Xile Chen, Nan Li, Yandong Zhong, Weixiang Wu, Guosheng Cai, Hui Jiang, Weiqin Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title_full | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title_fullStr | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title_full_unstemmed | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title_short | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
title_sort | soluble pd-l1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837921/ https://www.ncbi.nlm.nih.gov/pubmed/36639643 http://dx.doi.org/10.1186/s12967-023-03879-0 |
work_keys_str_mv | AT heyinjun solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT zhangxiang solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT zhuming solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT hewenguang solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT huahanju solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT yefeng solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT zhouxile solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT chennan solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT liyandong solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT zhongweixiang solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT wuguosheng solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT caihui solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer AT jiangweiqin solublepdl1apotentialdynamicpredictivebiomarkerforimmunotherapyinpatientswithproficientmismatchrepaircolorectalcancer |